Welcome to our dedicated page for Avant Technologies news (Ticker: AVAI), a resource for investors and traders seeking the latest updates and insights on Avant Technologies stock.
Avant Technologies Inc. (OTCQB: AVAI) issues frequent updates about its joint ventures, licensing agreements, and development programs in biotechnology and healthcare-focused artificial intelligence. Its news releases describe how the company is building a partnership-driven model around genetically modified cell lines, encapsulation technologies, and AI platforms that target chronic and age-related diseases.
Recent news has highlighted Avant’s joint venture with SGAustria Pte. Ltd. to form Insulinova, Inc., which is intended to develop cell-based therapies for type 1 and some insulin-dependent type 2 diabetes using insulin-producing cells combined with encapsulation technology. Other announcements cover the creation and progress of Klothonova, a 50/50 joint venture with Austrianova that is developing encapsulated Klotho-producing cell therapies for age-related conditions, including cardiovascular and neurodegenerative diseases.
Avant also reports on its collaboration with Ainnova Tech, Inc. through a joint venture that holds worldwide licensing rights to Ainnova’s Vision AI platform for early detection of diabetic retinopathy. News items describe regulatory interactions with the U.S. Food and Drug Administration, refinements to clinical trial protocols, and plans for patient recruitment in multiethnic populations at community and primary care sites.
Investors and observers following AVAI news can expect coverage of new joint venture agreements, updates on cell-based therapy programs, progress toward preclinical and clinical milestones, and developments in AI-based diagnostic initiatives. The company’s press releases also document corporate actions such as a proposed name change to Avaí Bio, Inc. and clarifications like the retraction of a previously announced but non-binding joint venture. This news feed allows readers to track how Avant’s partnership strategy evolves across its diabetes, longevity, and AI-driven healthcare efforts.
Avant Technologies (OTCQB:AVAI) and its partner Ainnova Tech announced that Ainnova will sponsor and participate in the 2025 Healthcare Innovation Summit in Mexico City. Ainnova's CEO, Vinicio Vargas, will be a featured speaker presenting on "Preventative Healthcare with Artificial Intelligence: Breaking the Status Quo."
The companies have formed Ai-nova Acquisition Corp. (AAC), which holds global licensing rights for Ainnova's technology portfolio, including its Vision AI platform and retinal cameras. The Healthcare Innovation Summit Series is a global event bringing together key healthcare stakeholders to discuss healthcare transformation, focusing on system optimization, digital transformation, diagnostic technology, and infrastructure.
Avant Technologies (OTCQB: AVAI) and Ainnova Tech have entered acquisition negotiations to strengthen their position in the AI-driven healthcare industry. The companies, which formed Ai-nova Acquisition Corp (AAC) six months ago, are looking to consolidate before their FDA pre-submission meeting in July 2025 regarding clinical trials for the Vision AI platform in diabetic retinopathy detection.
AAC currently holds worldwide licensing rights for Ainnova's technology portfolio, which includes the Vision AI platform and retinal cameras. The proposed merger aims to streamline the advancement of their technology to market and enhance resource utilization. The companies believe consolidating operations will facilitate their FDA interactions and accelerate their entry into the U.S. market.
Avant Technologies (OTCQB:AVAI) and its partner Ainnova Tech have initiated the design of their clinical trial protocol for the Vision AI platform, aimed at early detection of diabetic retinopathy. The company has hired an ophthalmologist to assist in drafting the protocol requirements for their CRO, Fortrea. The pre-submission meeting with the FDA is expected in mid-May 2025.
Ai-nova Acquisition Corp. (AAC), formed through the Avant-Ainnova partnership, holds global licensing rights for Ainnova's technology portfolio. The FDA pre-submission program will help determine the regulatory pathway, including patient and clinic requirements for clinical data generation, and help Avant establish a precise budget for the FDA process.
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have secured a pre-submission meeting with the FDA scheduled for July 7, 2025. The meeting will discuss their planned clinical trial for the Vision AI platform, designed for early detection of diabetic retinopathy. Through Ai-nova Acquisition Corp. (AAC), formed by the partnership, the companies aim to determine crucial trial parameters including the number of clinical sites, patient count, and protocol approval.
The meeting represents a significant step toward obtaining FDA 510(k) clearance for U.S. market entry. AAC holds worldwide licensing rights for Ainnova's technology portfolio, making successful FDA interactions crucial for commercialization in the United States market.
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have reached a significant milestone in their regulatory journey by requesting a pre-submission meeting with the FDA for their VisionAI platform technology.
The technology, focused on early detection of diabetic retinopathy, will be reviewed by the FDA's Center for Devices and Radiological Health. The companies aim to obtain FDA 510(k) clearance to market the technology in the U.S. through their partnership entity, Ai-nova Acquisition Corp (AAC).
Key points:
- AAC holds worldwide licensing rights for VisionAI platform and retinal cameras
- The strategy includes rapid deployment in low-regulation markets while pursuing FDA clearance
- Pre-submission meeting will help determine clinical trial requirements and budget planning
- Success with FDA is crucial for U.S. market entry and commercial potential
Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech are expanding their joint venture, Ai-nova Acquisition Corp (AAC), across Latin America following Ainnova's participation in the 2025 Healthcare Innovation Summit in Mexico City. The expansion includes commercial pilots in Chile and Dominican Republic hospitals, focusing on demonstrating cost reduction in preventive diagnostics and improved healthcare efficiency.
The pilots utilize Ainnova's Vision AI platform for real-time health risk identification, enabling specialty care referrals. The joint venture plans to deploy an automated retinal imaging device integrated with AI to screen for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images and basic health data.
AAC holds global licensing rights for Ainnova's technology portfolio. The companies are pursuing regulatory approvals in Brazil through MDSAP certification for ANVISA requirements, while simultaneously preparing for FDA clinical trials in the United States.
Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech announced that Ainnova will sponsor and present at the 2025 Healthcare Innovation Summit in Mexico City. Ainnova's CEO Vinicio Vargas will deliver a presentation titled 'Preventative Healthcare with Artificial Intelligence: Breaking the Status Quo.'
The companies have formed Ai-nova Acquisition Corp. (AAC), which holds global licensing rights for Ainnova's technology portfolio, including its Vision AI platform and retinal cameras. The Healthcare Innovation Summit Series is a global event bringing together key stakeholders such as government officials, regulators, hospital administrators, and clinical experts to discuss healthcare transformation, systems optimization, and digital innovation.
Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech have initiated the design of clinical trial protocols for their Vision AI platform, focusing on early detection of diabetic retinopathy. The companies are preparing for a pre-submission meeting with the FDA scheduled for mid-May 2025, which will guide the clinical testing requirements for their 510(k) clearance application.
An ophthalmologist has been hired to assist in drafting the trial protocol requirements requested by their Contract Research Organization (CRO), Fortrea. The technology is being developed through Ai-nova Acquisition Corp. (AAC), a joint venture holding global licensing rights to Ainnova's technology portfolio, including the Vision AI platform and retinal cameras.
The FDA pre-submission program will help determine the regulatory pathway, including patient and clinic requirements for clinical data generation, and enable Avant to establish a precise budget for the FDA process.
Avant Technologies (OTCQB:AVAI) and its partner Ainnova Tech have announced a strategic collaboration with Apollo Hospitals to advance AI in healthcare. Ainnova has secured exclusive licenses for AI algorithms validated with over 2.3 million data points for their Vision AI platform.
The platform enables early detection of various conditions including cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities. Following Avant and Ainnova's recent global development deal through their joint venture AAC, the AI diagnostics will be launched commercially across the Americas in the coming weeks.
The partnership has already received regulatory approval from ANVISA for expansion into Brazil's 200-million-person market. The collaboration aims to enhance chronic disease management by facilitating early referrals from primary care providers and community health services to specialists.
FAQ
What is the current stock price of Avant Technologies (AVAI)?
What is the market cap of Avant Technologies (AVAI)?
